Close Menu

Jefferies

Myriad and Cepheid discussed their pipelines, while Exact Sciences provided some details of its upcoming trial on its colon cancer test, and Danaher touted its success with past acquisitions as it nears closing of its Beckman Coulter buy.

Complete Genomics CEO Clifford Reid outlined goals for his firm, while Affymetrix CFO Tim Barabe spoke about market opportunities and a shift in the firm's business model.

Jefferies also increased the firm's stock price target to $20 from $15.50.

The Jefferies analyst also elevated the target share price for Agilent on expectations of healthy organic revenues and "immaterial" effects from the Japanese earthquake and tsunami on Agilent's business.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.